Few Worries As Modern Insulins Drive Novo’s China Growth
This article was originally published in PharmAsia News
The possibility of slowing growth in China does not seem to be a concern for investors in Novo Nordisk, which reported a steady rise in its business in this key emerging market in the first quarter.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.